HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

panitumumab (Vectibix)

Subscribe to New Research on panitumumab

antibody that blocks receptors for epidermal growth factor; approved for advanced colon cancer

Also Known As:

Vectibix; ABX-EGF MAb; ABX-EGF monoclonal antibody; Amgen brand of panitumumab; panitumumab antibody, human; Immunoglobulin, anti-(human epidermal growth factor receptor) (human monoclonal ABX-EGF heavy chain), disulfide with human monoclonal ABX-EGF light chain, dimer

Networked: 546 relevant articles (94 outcomes, 160 trials/studies)

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins
- Proteins: 90489
  - Blood Proteins: 4303
    - Serum Globulins: 75
      - Immunoglobulins: 23980
        Antibodies: 92632
        Monoclonal Antibodies: 18549
        panitumumab: 546
    - Immunoproteins: 33
      - Immunoglobulins: 23980
        Antibodies: 92632
        Monoclonal Antibodies: 18549
        panitumumab: 546
  - Globulins: 334
    - Serum Globulins: 75
      - Immunoglobulins: 23980
        Antibodies: 92632
        Monoclonal Antibodies: 18549
        panitumumab: 546

Experts

1.	Siena, Salvatore: 24 articles (10/2015 - 05/2005)
2.	Sartore-Bianchi, Andrea: 16 articles (10/2015 - 05/2005)
3.	Bardelli, Alberto: 15 articles (07/2015 - 05/2005)
4.	Van Cutsem, Eric: 14 articles (12/2015 - 01/2007)
5.	Peeters, Marc: 14 articles (12/2015 - 05/2007)
6.	Di Nicolantonio, Federica: 13 articles (07/2015 - 05/2005)
7.	Tabernero, Josep: 11 articles (11/2015 - 12/2008)
8.	Hecht, J Randolph: 11 articles (09/2015 - 01/2006)
9.	Oliner, Kelly S: 10 articles (12/2015 - 11/2010)
10.	Amado, Rafael G: 10 articles (04/2009 - 03/2007)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 09/01/2015 - "Panitumumab has proven efficacy in patients with metastatic or locally advanced colorectal cancer patients, provided that they have no activating KRAS mutation in their tumour. " 12/03/2007 - "In a randomised phase 3 trial, panitumumab significantly improved progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC). " 05/01/2007 - "Panitumumab significantly improved PFS with manageable toxicity in patients with chemorefractory colorectal cancer." 11/01/2015 - "Although the anti-EGFR monoclonal antibody panitumumab is effective in treating colorectal cancer, the occurrence of severe skin disorders often discontinues therapy. " 10/01/2012 - "Our findings suggested that panitumumab has great potential for effective treatment of patients with unresectable stageIV colorectal cancer."
2.	Neoplasms (Cancer) 01/01/2014 - "In patients with WT KRAS tumors, panitumumab-FOLFIRI significantly improved PFS versus FOLFIRI [median 6.7 versus 4.9 months; hazard ratio (HR) 0.82 [95% confidence interval (CI) 0.69, 0.97]; P = 0.023]. " 01/01/2012 - "The LS-174T tumor AUC of 204.13 ± 9.67 was significantly greater (P < 0.001) than the LS-174T tumor AUC of 36.45 ± 1.39 obtained from mice coinjected with 0.1 mg of panitumumab for blocking the target. " 06/01/2014 - "However, active initiation as first-line treatment should be considered for cases in which resection of metastatic foci can be expected from tumor reductions due to panitumumab. " 03/01/2012 - "Improved tumor response was also observed with the addition of panitumumab to FOLFIRI. " 09/01/2011 - "Panitumumab plus FOLFIRI numerically improved objective response rate, PFS, and OS in favor of patients with wild-type KRAS tumors. "
3.	Sarcoma (Soft Tissue Sarcoma) 12/01/2015 - "Panitumumab and cetuximab have improved tumour response rate, progression-free survival, and OS in mCRC patients in whom the RAS (Rat Sarcoma) gene is of Wild Type (WT) status. " 10/01/2012 - "In the Greek NHS and Social Security Sickness Fund setting, panitumumab monotherapy potentially constitutes a cost-saving option (versus cetuximab monotherapy) in the management of patients with mCRC and no mutation of Kirsten rat sarcoma viral oncogene homolog." 06/01/2013 - "The randomized first-line trials, including the CRYSTAL trial, the OPUS trial, and the PRIME trial, have demonstrated the significant efficacy of cetuximab or panitumumab in patients with v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type tumors. " 10/01/2012 - "The aim of this study was to conduct a cost-minimization analysis comparing panitumumab with cetuximab in the treatment of patients with epidermal growth factor receptor-expressing mCRC with nonmutated (wild-type) Kirsten rat sarcoma viral oncogene homolog in Greece. " 11/01/2015 - "The aim of the study was to investigate the efficacy and tolerability of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in combination with pemetrexed/cisplatin in patients with stage IIIB to IV primary nonsquamous non-small-cell lung cancer and wild type V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS). "
4.	Disease Progression 06/01/2013 - "Results from the primary analysis of a phase 3, randomized, controlled study showed a statistically significant improvement in progression-free survival for patients receiving panitumumab; however, overall survival was confounded by best supportive care (BSC) patients that crossed over to panitumumab therapy after disease progression. " 01/01/2012 - "Treatment was continued until disease progression, death, inability to tolerate panitumumab, or study withdrawal. " 06/07/2011 - "As the trial design allowed patients on BSC alone to receive panitumumab after disease progression, which confounded overall survival (OS), the focus of this analysis was on PFS. " 08/01/2008 - "In a randomized phase 3 study (463 patients), panitumumab almost halved the risk of disease progression/death vs. a control group receiving only best supportive care (hazard ratio 0.54; 95% CI: 0.44-0.66; P < 0.0001). " 01/01/2008 - "This open-label extension study evaluated panitumumab monotherapy in BSC patients with radiographically documented disease progression in the phase 3 study. "
5.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/01/2013 - "RTOG 0839 is a Phase II study of pre-operative chemoradiotherapy with or without panitumumab in potentially operable locally advanced non-small cell lung cancer (NSCLC). " 10/01/2013 - "Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab." 09/01/2015 - "Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor--Mutated Non--Small-Cell Lung Cancer With T790M Mutations." 06/01/2009 - "We investigated the activity of panitumumab, a fully human anti-EGFR monoclonal antibody, in vitro in mutant EGFR-expressing non-small cell lung carcinoma (NSCLC) cells and in vivo with chemotherapy in xenograft models. " 07/01/2006 - "Panitumumab has demonstrated efficacy as monotherapy and with standard chemotherapeutic agents in a wide variety of cancer types, including non-small-cell lung cancer, renal, and colorectal cancer (CRC). "

Related Drugs and Biologics

1.	cetuximab (Erbitux)
2.	bevacizumab
3.	Monoclonal Antibodies
4.	Epidermal Growth Factor Receptor (EGF Receptor)
5.	oxaliplatin (Eloxatin)
6.	irinotecan (Camptosar)
7.	Fluorouracil (Carac)
8.	Leucovorin (Folinic Acid)
9.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
10.	Antibodies

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Heterologous Transplantation (Xenotransplantation)
3.	Combination Drug Therapy (Combination Chemotherapy)
4.	Molecular Targeted Therapy
5.	Radiotherapy